# Rifaximin Use in Severe Alcoholic Hepatitis

> **NCT02485106** · PHASE3 · UNKNOWN · sponsor: **Saint Vincent's Hospital, Korea** · enrollment: 170 (estimated)

## Conditions studied

- Severe Alcoholic Hepatitis

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Corticosteroid or pentoxifylline

## Key facts

- **NCT ID:** NCT02485106
- **Lead sponsor:** Saint Vincent's Hospital, Korea
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2016-12
- **Final completion:** —
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2015-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02485106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02485106, "Rifaximin Use in Severe Alcoholic Hepatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02485106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*